Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R1441G) transgenic mouse

Neuroscience Letters

Volumn 549, Issue , 2013, Pages 57-62

  Dranka, Brian P ^a   Gifford, Alison ^a   Ghosh, Anamitra ^b,c   Zielonka, Jacek ^a   Joseph, Joy ^a   Kanthasamy, Anumantha G ^b   Kalyanaraman, Balaraman ^a  

^a FREE RADICAL RESEARCH CENTER   (United States)

^b IOWA STATE UNIVERSITY   (United States)

^c VAN ANDEL RESEARCH INSTITUTE   (United States)

Author keywords

Neurobehavioral analysis; Neurodegeneration; Parkinson's disease

Indexed keywords

ANTIINFLAMMATORY AGENT; DIAPOCYNIN; LEUCINE RICH REPEAT KINASE 2; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; MALE; MOTOR COORDINATION; MOTOR DYSFUNCTION; MOUSE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBSTANTIA NIGRA; TASK PERFORMANCE; TRANSGENE;

LEUCINE-RICH REPEAT KINASE 2; LRRK2; NADPH; NADPH OXIDASE ISOFORM 2; NEUROBEHAVIORAL ANALYSIS; NEURODEGENERATION; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE (REDUCED FORM); NON-STEROIDAL ANTI-INFLAMMATORY DRUG; NOX2; NSAID; PARKINSON'S DISEASE; PD; PHORBOL-12-MYRISTATE-13-ACETATE; PMA; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES; RNS; ROS; TH; TYROSINE HYDROXYLASE;

ACETOPHENONES; ANIMALS; BIPHENYL COMPOUNDS; DISEASE MODELS, ANIMAL; GAIT; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; PARKINSON DISEASE; PROTEIN-SERINE-THREONINE KINASES; ROTAROD PERFORMANCE TEST;

EID: 84880750830     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.05.034     Document Type: Article

References (31)

1. Baptista M., Dave K., De Silva S., Sasner M., Gorodinsky A., Beck M., Quang C., Gamber K., Reith A., Lyon J., Roulois A., Aziz Y., Das S., Eberling J., Dufour A., Facheris M., Fiske B., Sheth N., Sherer T., Urkowitz A., Frasier M. MJFF Animal Models 2: generation, characterization, and distribution of LRRK2 animal models for Parkinson's research. Program No. 854.822. 2012 Neuroscience Meeting Planner 2012, Society for Neuroscience, New Orleans, LA, Online.
2. Beal M.F. Bioenergetic approaches for neuroprotection in Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S39-S47. discussion S47-38.
3. Bedard K., Krause K.H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol. Rev. 2007, 87:245-313.
4. Cristovao A.C., Choi D.H., Baltazar G., Beal M.F., Kim Y.S. The role of NADPH oxidase 1-derived reactive oxygen species in paraquat-mediated dopaminergic cell death. Antioxid. Redox Signal. 2009, 11:2105-2118.
5. Driver J.A., Logroscino G., Lu L., Gaziano J.M., Kurth T. Use of non-steroidal anti-inflammatory drugs and risk of Parkinson's disease: nested case-control study. BMJ 2011, 342:d198.
6. Dumont M., Stack C., Elipenhali C., Calingasan N.Y., Wille E., Beal M.F. Apocynin administration does not improve behavioral and neuropathological deficits in a transgenic mouse model of Alzheimer's disease. Neurosci. Lett. 2011, 492:150-154.
7. Duty S., Jenner P. Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br. J. Pharmacol. 2011, 164:1357-1391.
8. Elbs K., Lerch H. Über dehydrodivanillin. J. Prakt. Chem. 1916, 93:1-9.
9. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002.
10. Ghosh A., Kanthasamy A., Joseph J., Anantharam V., Srivastava P., Dranka B.P., Kalyanaraman B., Kanthasamy A.G. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease. J. Neuroinflamm. 2012, 9:241-256.
11. Gillardon F., Schmid R., Draheim H. Parkinson's disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 2012, 208:41-48.
12. Graeber M.B., Streit W.J. Microglia: biology and pathology. Acta Neuropathol. 2010, 119:89-105.
13. Greggio E., Cookson M.R. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions. ASN Neuro 2009, 1:13-24.
14. Heumuller S., Wind S., Barbosa-Sicard E., Schmidt H.H., Busse R., Schroder K., Brandes R.P. Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant. Hypertension 2008, 51:211-217.
15. Khan N.L., Jain S., Lynch J.M., Pavese N., Abou-Sleiman P., Holton J.L., Healy D.G., Gilks W.P., Sweeney M.G., Ganguly M., Gibbons V., Gandhi S., Vaughan J., Eunson L.H., Katzenschlager R., Gayton J., Lennox G., Revesz T., Nicholl D., Bhatia K.P., Quinn N., Brooks D., Lees A.J., Davis M.B., Piccini P., Singleton A.B., Wood N.W. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005, 128:2786-2796.
16. Kim B., Yang M.S., Choi D., Kim J.H., Kim H.S., Seol W., Choi S., Jou I., Kim E.Y., Joe E.H. Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS ONE 2012, 7:e34693.
17. Li Y., Liu W., Oo T.F., Wang L., Tang Y., Jackson-Lewis V., Zhou C., Geghman K., Bogdanov M., Przedborski S., Beal M.F., Burke R.E., Li C. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat. Neurosci. 2009, 12:826-828.
18. Martin I., Dawson V.L., Dawson T.M. The impact of genetic research on our understanding of Parkinson's disease. Prog. Brain Res. 2010, 183:21-41.
19. McGeer P.L., McGeer E.G. Glial reactions in Parkinson's disease. Mov. Disord. 2008, 23:474-483.
20. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
21. Petronio M.S., Zeraik M.L., Fonseca L.M., Ximenes V.F. Apocynin: chemical and biophysical properties of a NADPH oxidase inhibitor. Molecules 2013, 18:2821-2839.
22. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
23. Schapira A.H., Agid Y., Barone P., Jenner P., Lemke M.R., Poewe W., Rascol O., Reichmann H., Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson's disease. Eur. J. Neurol. 2009, 16:1090-1099.
24. Sherer T.B., Betarbet R., Kim J.H., Greenamyre J.T. Selective microglial activation in the rat rotenone model of Parkinson's disease. Neurosci. Lett. 2003, 341:87-90.
25. Simonyi A., Serfozo P., Lehmidi T.M., Cui J., Gu Z., Lubahn D.B., Sun A.Y., Sun G.Y. The neuroprotective effects of apocynin. Front. Biosci. (Elite Ed.) 2012, 4:2183-2193.
26. Stefanska J., Pawliczak R. Apocynin: molecular aptitudes. Mediators Inflamm. 2008, 2008:106507.
27. Surace M.J., Block M.L. Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cell. Mol. Life Sci. 2012, 69:2409-2427.
28. The Jackson Lab LRRK2R1441G strain development information. (accessed 30.10.2012). http://jaxmice.jax.org/strain/009604.html.
29. Trumbull K.A., McAllister D., Gandelman M.M., Fung W.Y., Lew T., Brennan L., Lopez N., Morre J., Kalyanaraman B., Beckman J.S. Diapocynin and apocynin administration fails to significantly extend survival in G93A SOD1 ALS mice. Neurobiol. Dis. 2012, 45:137-144.
30. Wang Q., Smith R.E., Luchtefeld R., Sun A.Y., Simonyi A., Luo R., Sun G.Y. Bioavailability of apocynin through its conversion to glycoconjugate but not to diapocynin. Phytomedicine 2008, 15:496-503.
31. Zielonka J., Zielonka M., Sikora A., Adamus J., Joseph J., Hardy M., Ouari O., Dranka B.P., Kalyanaraman B. Global profiling of reactive oxygen and nitrogen species in biological systems: high-throughput real-time analyses. J. Biol. Chem. 2012, 287:2984-2995.